Clinical Evidence
Claims, with evidence
We present each claim with its evidence and a transparent footnote — in line with responsible medical-device communication.
Perfusion support
Alternating-pressure pulsation increased tissue oxygen saturation (p = 0.04) and skin blood flow (p = 0.001) in internal evaluation.
Internal evaluation. AERIS is designed to support — not guarantee — these outcomes.
Microclimate management
25–40°C low-air-loss airflow at 0.3 m/min helps maintain a dry skin interface, supporting the barrier against moisture-associated skin damage.
Mechanism-based; outcomes vary by patient and setting.
Pressure redistribution
AERIS TX reduces interface pressure to 13.5–32 mmHg across 19 air-cell zones, below the ~32 mmHg capillary closing pressure.
Measured at the support-surface interface; values depend on patient weight and posture.
AERIS therapy mattresses are medical devices. Regulatory clearances and availability vary by market. Not intended to diagnose, treat, cure or prevent any disease. This material is for professional and informational use and is not a substitute for clinical judgment.